MARKET

PIRS

PIRS

Pieris Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.950
+0.050
+1.28%
After Hours: 3.950 0 0.00% 17:26 11/11 EST
OPEN
4.050
PREV CLOSE
3.900
HIGH
4.180
LOW
3.760
VOLUME
1.12M
TURNOVER
--
52 WEEK HIGH
6.04
52 WEEK LOW
2.390
MARKET CAP
195.10M
P/E (TTM)
-5.1179
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of PIRS and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

PIRS News

  • Pieris Pharmaceuticals (PIRS) Reports Q3 Loss, Tops Revenue Estimates
  • Zacks.5h ago
  • Pieris Pharmaceuticals EPS beats by $0.18, beats on revenue
  • seekingalpha.6h ago
  • Pieris Pharma +4% premarket on Q3 beat
  • Seeking Alpha - Article.11h ago
  • Pieris Pharmaceuticals Q3 EPS $(0.05) Beats $(0.23) Estimate, Sales $15.132M Beat $6.42M Estimate
  • Benzinga.11h ago

More

Industry

Biotechnology & Medical Research
-0.51%
Pharmaceuticals & Medical Research
-0.43%

Hot Stocks

Name
Price
%Change

About PIRS

Pieris Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids. It is focused on developing three drug candidates, which include PRS-080, PRS-060 and PRS-300 series. Its PRS-080 is an Anticalin drug candidate targeting hepcidin. The Company's second Anticalin drug candidate, PRS-060, binds to the IL-4 receptor alpha-chain (IL-4RA), thereby inhibiting the actions of IL-4 and IL-13, two cytokines known to be mediators in the inflammatory cascade that causes asthma and other inflammatory diseases. PRS-343 is an Anticalin-based drug candidate.
More

Webull offers Pieris Pharmaceuticals Inc (PIRS) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.